Recent Advances in Allergen-Specific Immunotherapy in Humans: A Systematic Review

키워드

참고문헌 (79)

1. Noon L, "Prophylactic inoculation against hay fever", Lancet, 1, pp.1572~1573 (1911)
2. Hoffmann HJ, "Novel approaches and perspectives in allergen immunotherapy", Allergy, 72, pp.1022~1034 (2017)
3. Canonica GW, "Noninjection routes for immunotherapy", J Allergy Clin Immunol, 111, pp.437~448 (2003)
4. Kim ST, "Allergen-specific intralymphatic immunotherapy in human and animal studies", Asia Pac Allergy, 7, pp.131~137 (2017)
5. Durham SR, "Sublingual or subcutaneous immunotherapy for allergic rhinitis", J Allergy Clin Immunol, 137, pp.339~349 (2016)
6. Senti G, "Novel delivery routes for allergy immunotherapy : intralymphatic, epicutaneous, and intradermal", Immunol Allergy Clin North Am, 36, pp.25~37 (2016)
7. Kersey TW, "Comparison of intradermal and subcutaneous injections in lymphatic mapping", J Surg Res, 96, pp.255~259 (2001)
8. O’Mahony S, "Imaging of lymphatic vessels in breast cancer-related lymphedema : intradermal versus subcutaneous injection of 99mTcimmunoglobulin", AJR Am J Roentgenol, 186, pp.1349~1355 (2006)
9. Rotiroti G, "Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses", J Allergy Clin Immunol, 130, pp.918~924 (2012)
10. Scheurer S, "Epicutaneous immunotherapy", Allergol Immunopathol (Madr), 45(Suppl 1), pp.25~29 (2017)
11. Senti G, "Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy", J Allergy Clin Immunol, 124, pp.997~1002 (2009)
12. Dickel H, "Standardized tape stripping : a practical and reproducible protocol to uniformly reduce the stratum corneum", Skin Pharmacol Physiol, 23, pp.259~265 (2010)
13. NickoloffBJ, "Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin", J Am Acad Dermatol, 30, pp.535~546 (1994)
14. Dickel H, "Standardized tape stripping prior to patch testing induces upregulation of Hsp90, Hsp70, IL-33, TNF-α and IL-8", CXCL8 mRNA : new insights into the involvement of ‘alarmins’, 2010, pp.63, 215~222
15. Senti G, "Intralymphatic immunotherapy : from the rationale to human applications", Curr Top Microbiol Immunol, 352, pp.71~84 (2011)
16. Martínez-Gómez JM, "Intralymphatic injections as a new administration route for allergen-specific immunotherapy", Int Arch Allergy Immunol, 150, pp.59~65 (2009)
17. Senti G, "Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections", J Allergy Clin Immunol, 129, pp.1290~1296 (2012)
18. Hylander T, "Intralymphatic allergen-specific immunotherapy : an effective and safe alternative treatment route for pollen-induced allergic rhinitis", J Allergy Clin Immunol, 131, pp.412~420 (2013)
19. Hylander T, "Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis : a double-blind placebo-controlled trial", Respir Res, 17, pp.10~ (2016)
20. Hellkvist L, "Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass : a randomized, doubleblind, placebo-controlled trial", J Allergy Clin Immunol, 142, pp.1338~1341 (2018)
21. Freiberger SN, "IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human", Allergy, 71, pp.1366~1370 (2016)
22. Ahlbeck L, "Intralymphatic allergen immunotherapy against pollen allergy : a 3-year open follow-up study of 10 patients", Ann Allergy Asthma Immunol, 121, pp.626~627 (2018)
23. Witten M, "Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy", J Allergy Clin Immunol, 132, pp.1248~1252 (2013)
24. Schmid JM, "Intralymphatic immunotherapy induces allergen specific plasmablasts and increases tolerance to skin prick testing in a pilot study", Clin Transl Allergy, 6, pp.19~ (2016)
25. 이상표, "A Pilot Study of Intralymphatic Immunotherapy for House Dust Mite, Cat, and Dog Allergies", Allergy, Asthma & Immunology Research, 9(3), pp.272~277 (2017), 대한천식알레르기학회
26. Skaarup SH, "Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis : A 3-year randomized placebo-controlled trial", J Allergy Clin Immunol, 147, pp.1011~1019 (2021)
27. Weinfeld D, "A preseason booster prolongs the increase of allergen specific IgG4 levels, after basic allergen intralymphatic immunotherapy, against grass pollen seasonal allergy", Allergy Asthma Clin Immunol, 16, pp.31~ (2020)
28. Konradsen JR, "Intralymphatic immunotherapy in pollen-allergic young adults with rhinoconjunctivitis and mild asthma : a randomized trial", J Allergy Clin Immunol, 145, pp.1005~1007 (2020)
29. 강성윤, "임파선내항원특이면역요법", Allergy Asthma & Respiratory Disease, 8(2), pp.53~65 (2020), 대한 소아알레르기 호흡기학회[DOI]
30. Slovick A, "Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms", J Allergy Clin Immunol, 139, pp.1830~1839 (2017)
31. Sola Martínez FJ, "Intradermal Phleum pratense allergoid immunotherapy. Double-blind, randomized, placebo-controlled trial", Clin Exp Allergy, 50, pp.1352~1361 (2020)
32. Senti G, "Determinants of efficacy and safety in epicutaneous allergen immunotherapy : summary of three clinical trials", Allergy, 70, pp.707~710 (2015)
33. Senti G, "Epicutaneous allergenspecific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis : a double-blind, placebocontrolled dose escalation study", J Allergy Clin Immunol, 129, pp.128~135 (2012)
34. von Moos S, "Comparing safety of abrasion and tapestripping as skin preparation in allergen-specific epicutaneous immunotherapy", J Allergy Clin Immunol, 134, pp.965~967 (2014)
35. Agostinis F, "Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis", Allergy, 65, pp.410~411 (2010)
36. Dupont C, "Cow’s milk epicutaneous immunotherapy in children : a pilot trial of safety, acceptability, and impact on allergic reactivity", J Allergy Clin Immunol, 125, pp.1165~1167 (2010)
37. Jones SM, "Safety of epicutaneous immunotherapy for the treatment of peanut allergy : a phase 1study using the Viaskin patch", J Allergy Clin Immunol, 137, pp.1258~1261 (2016)
38. Jones SM, "Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults", J Allergy Clin Immunol, 139, pp.1242~1252 (2017)
39. Sampson HA, "Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity : a randomized clinical trial", JAMA, 318, pp.1798~1809 (2017)
40. Fleischer DM, "Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy : the PEPITES randomized clinical trial", JAMA, 321, pp.946~955 (2019)
41. Spergel JM, "Efficacy of epicutaneous immunotherapy in children with milk-induced eosinophilic esophagitis", Clin Gastroenterol Hepatol, 18, pp.328~336 (2020)
42. Xiong L, "The efficacy and safety of epicutaneous immunotherapy for allergic diseases : a systematic review and meta-analysis", Int Arch Allergy Immunol, 181, pp.170~182 (2020)
43. Park HJ, "Intralymphatic immunotherapy with tyrosine-adsorbed allergens : a double-blind, placebo-controlled trial", Respir Res, 22, pp.170~ (2021)
44. Senti G, "Intralymphatic allergen administration renders specific immunotherapy faster and safer : a randomized controlled trial", Proc Natl Acad Sci U S A, 105, pp.17908~17912 (2008)
45. Patterson AM, "Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis", Ann Allergy Asthma Immunol, 116, pp.168~170 (2016)
46. 이상표, "Intralymphatic Immunotherapy Alleviates Allergic Symptoms During Allergen Exposure in Daily Life", Allergy, Asthma & Immunology Research, 10(2), pp.180~181 (2018), 대한천식알레르기학회
47. Terada T, "Sustained effects of intralymphatic pollen-specific immunotherapy on Japanese cedar pollinosis", Rhinology, 58, pp.241~247 (2020)
48. Thompson CP, "Intralymphatic immunotherapy for mountain cedar pollinosis : A randomized, double-blind, placebo-controlled trial", Ann Allergy Asthma Immunol, 125, pp.311~318 (2020)
49. Wang K, "Clinical efficacy and safety of cervical intralymphatic immunotherapy for house dust mite allergic rhinitis : a pilot study", Am J Otolaryngol, 40, pp.102280~ (2019)
50. Werner MT, "Intralymphatic immunotherapy for allergic rhinitis : a systematic review and metaanalysis", Allergy Asthma Proc, 42, pp.283~292 (2021)
51. Hoang MP, "Intralymphatic immunotherapy for allergic rhinoconjunctivitis : a systematic review and meta-analysis", Rhinology, 59, pp.236~244 (2021)
52. Kündig TM, "Intralymphatic immunotherapy : time interval between injections is essential", J Allergy Clin Immunol, 133, pp.930~931 (2014)
53. Henmar H, "Allergenicity, immunogenicity and doserelationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy", Clin Exp Immunol, 153, pp.316~323 (2008)
54. Skaarup SH, "The number of successful injections associates with improved clinical effect in intralymphatic immunotherapy", Allergy, 76, pp.1859~1861 (2021)
55. Aini NR, "Efficacy and safety of intralymphatic immunotherapy in allergic rhinitis : a systematic review and meta-analysis", Clin Transl Allergy, 11, pp.e12055~ (2021)
56. Norman PS, "Controlled evaluations of repository therapy in ragweed hay fever", J Allergy, 39, pp.82~92 (1967)
57. Norman PS, "Trials of alum-precipitated pollen extracts in the treatment of hay fever", J Allergy Clin Immunol, 50, pp.31~44 (1972)
58. Casanovas M, "Double-blind study of tolerability and antibody production of unmodified and chemically modified allergen vaccines of Phleum pratense", Clin Exp Allergy, 35, pp.1377~1383 (2005)
59. Pfaar O, "Immunotherapy with depigmented-polymerized mixed tree pollen extract : a clinical trial and responder analysis", Allergy, 65, pp.1614~1621 (2010)
60. DuBuske LM, "Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen", Allergy Asthma Proc, 32, pp.239~247 (2011)
61. Klimek L, "Virus-like particles(VLP)in prophylaxis and immunotherapy of allergic diseases", Allergo J Int, 27, pp.245~255 (2018)
62. Pechsrichuang Phornsiri, "Bioengineering of Virus-like Particles for the Prevention or Treatment of Allergic Diseases", Allergy, Asthma & Immunology Research, 13(1), pp.23~41 (2021), 대한천식알레르기학회[DOI]
63. 김주형, "Virus-like Particle (VLP) Mediated Antigen Delivery as a Sensitization Tool of Experimental Allergy Mouse Models", Immune Network, 20(4), pp.1~13 (2020), 대한면역학회[DOI]
64. Nelson HS, "Middleton’s Allergy Principles and Practice", pp.1401~1419 (2020), Elsevier
65. Jutel M, "Allergen-specific immunotherapy with recombinant grass pollen allergens", J Allergy Clin Immunol, 116, pp.608~613 (2005)
66. Pauli G, "Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis", J Allergy Clin Immunol, 122, pp.951~960 (2008)
67. Klimek L, "Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial", Clin Transl Allergy, 5, pp.28~ (2015)
68. Norman PS, "Treatment of cat allergy with T-cell reactive peptides", Am J Respir Crit Care Med, 154, pp.1623~1628 (1996)
69. Maguire P, "The safety and efficacy of ALLERVAX CAT in cat allergic patients", Clin Immunol, 93, pp.222~231 (1999)
70. Worm M, "Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy", J Allergy Clin Immunol, 127, pp.89~97 (2011)
71. Couroux P, "Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects", Clin Exp Allergy, 45, pp.974~981 (2015)
72. Spertini F, "Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis : Results of a phase IIb study", J Allergy Clin Immunol, 138, pp.162~168 (2016)
73. Broide D, "Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice", J Immunol, 161, pp.7054~7062 (1998)
74. Tighe H, "Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity", J Allergy Clin Immunol, 106, pp.124~134 (2000)
75. Creticos PS, "Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis", N Engl J Med, 355, pp.1445~1455 (2006)
76. Klimek L, "Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis : a phase IIb study", Clin Exp Allergy, 41, pp.1305~1312 (2011)
77. Senti G, "Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans : a phase I", IIa clinical trial, 2009, pp.39, 562~570
78. Sirvent S, "Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1", J Allergy Clin Immunol, 138, pp.558~567 (2016)
79. Saxon A, ""Accentuate the negative, eliminate the positive" : engineering allergy therapeutics to block allergic reactivity through negative signaling", J Allergy Clin Immunol, 121, pp.320~325 (2008)

관련 논문AI추천